A phase II/III randomized clinical trial to study the efficacy and safety of the combination regimen of MK-5172 and MK-8742 in subjects with chronic hepatitis C virus infection and chronic kidney disease

Trial Profile

A phase II/III randomized clinical trial to study the efficacy and safety of the combination regimen of MK-5172 and MK-8742 in subjects with chronic hepatitis C virus infection and chronic kidney disease

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Elbasvir (Primary) ; Grazoprevir (Primary)
  • Indications Hepatitis C; Kidney disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-SURFER
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Feb 2017 Results of an integrated analysis of this trial and 5 other trails (see profiles 225044, 243158, 243227, 243234, 243273) published in the Gastroenterology
    • 29 Jul 2016 According to a Merck media release, Zepatier (elbasvir/grazoprevir) with or without ribavirin has been approved in the European Union for the treatment of chronic hepatitis C virus genotype 1-4 infections in adults.
    • 28 Jan 2016 According to a Merck & Co. media release, Zepatier (elbasvir and grazoprevir) has received US FDA approval for use in treatment of Chronic Hepatitis C virus genotype 1 or 4 infection in adults. The approval was based on six trials (CTPs - 700243227, 700243234, 700242414, 700243273, 700243158 and 700236483).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top